Literature DB >> 7647962

Effect of a 5-HT1 receptor agonist, CP-122,288, on oedema formation induced by stimulation of the rat saphenous nerve.

R Kajekar1, P Gupta, N B Shepperson, S D Brain.   

Abstract

Neurogenic oedema formation in the rat hind paw skin induced by electrical stimulation of the saphenous nerve and measured by extravasation of [125I]-albumin, was inhibited by the 5-HT1B receptor agonist, CP-93,129, and the novel tryptamine analogue, CP-122,288. Significant inhibition of up to 66% of control was observed with CP-122,288 (2 x 10(-14) - 2 x 10(-7) mol kg-1) and CP-93,129 (5 x 10(-7) - 5 x 10(-6) mol kg-1), with the minimum effective dose for CP-122,288 being about 10(7) fold less than that for CP-93,129. Oedema formation induced by the intradermal administration of exogenous mediators (substance P and histamine) in rat dorsal skin was not inhibited by CP-122,288 (2 x 10(-10) mol kg-1). These results suggest that CP-122,288 is a potent inhibitor of neurogenic inflammation in rat skin and that the effect may be due to a prejunctional inhibition of neuropeptide release.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7647962      PMCID: PMC1908755          DOI: 10.1111/j.1476-5381.1995.tb16310.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  8 in total

1.  CP-93,129, a potent and selective 5-HT1B receptor agonist blocks neurogenic plasma extravasation within rat but not guinea-pig dura mater.

Authors:  T Matsubara; M A Moskowitz; B Byun
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

2.  Pharmacological properties of a potent and selective nonpeptide substance P antagonist.

Authors:  C Garret; A Carruette; V Fardin; S Moussaoui; J F Peyronel; J C Blanchard; P M Laduron
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

3.  Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation.

Authors:  F Lembeck; P Holzer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-12       Impact factor: 3.000

4.  Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638 exhibit enhanced potency against neurogenic inflammation in dura mater.

Authors:  W S Lee; M A Moskowitz
Journal:  Brain Res       Date:  1993-10-29       Impact factor: 3.252

5.  The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater.

Authors:  M G Buzzi; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

6.  Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability.

Authors:  S D Brain; T J Williams
Journal:  Br J Pharmacol       Date:  1985-12       Impact factor: 8.739

Review 7.  Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.

Authors:  M A Moskowitz
Journal:  Trends Pharmacol Sci       Date:  1992-08       Impact factor: 14.819

8.  Effect of a calcitonin gene-related peptide antagonist (CGRP8-37) on skin vasodilatation and oedema induced by stimulation of the rat saphenous nerve.

Authors:  K J Escott; S D Brain
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

  8 in total
  3 in total

1.  High affinity P2x-purinoceptor binding sites for [35S]-adenosine 5'-O-[3-thiotriphosphate] in rat vas deferens membranes.

Authors:  A D Michel; P P Humphrey
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

2.  The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation.

Authors:  P Gupta; D Brown; P Butler; P Ellis; K L Grayson; G C Land; J E Macor; S F Robson; M J Wythes; N B Shepperson
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

3.  TRPA1 is essential for the vascular response to environmental cold exposure.

Authors:  Aisah A Aubdool; Rabea Graepel; Xenia Kodji; Khadija M Alawi; Jennifer V Bodkin; Salil Srivastava; Clive Gentry; Richard Heads; Andrew D Grant; Elizabeth S Fernandes; Stuart Bevan; Susan D Brain
Journal:  Nat Commun       Date:  2014-12-11       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.